16 unknown, 6 recruiting, 5 completed, 2 not yet recruiting. 22 Phase 2, 8 Phase 3, 3 Phase 1, 1 Phase 4.
Follow gimeracil: new trials by email Literature Review of gimeracil trials Research Report on gimeracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 720 | 2026-07-31 | 2026-08-14 |
| Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer GFH375, Chemotherapy - Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 320 | 2025-12-04 | 2026-08-14 |
| Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab. - Hepatoid Adenocarcinoma of Stomach | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 30 | 2025-09-18 | 2025-12-02 |
| Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients Huaier granule, Oxaliplatin, Tegafur, Gimeracil and Oteracil Potassium - Gastric Cancer | Phase 4 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 702 | 2024-07-01 | 2024-06-24 |
| RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer RC48, Adebrelimab, Apatinib - Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 32 | 2024-05-01 | 2024-05-13 |
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) S-1, Toripalimab, Intensity-modulated radiotherapy - Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 140 | 2024-03-01 | 2024-03-12 |
| A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study LM-302, Toripalimab, Capecitabine - Malignant Neoplasms of Digestive Organs | Phase 2 | Recruiting | LaNova Medicines Zhejiang Co., Ltd. | 632 | 2023-07-27 | 2026-10-19 |
| Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases Oxaliplatin, S1, Cetuximab - For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method | Phase 2 | Unknown | Liaoning Cancer Hospital & Institute | 100 | 2023-03-15 | 2023-03-20 |
| Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC Fruquintinib, S-1, raltitrexed - Fruquintinib, S-1 | Phase 2 | Unknown | Meng Qiu | 66 | 2023-02-20 | 2025-01-22 |
| Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer Envafolimab plus Endostar and S-1, Envafolimab plus Endostar, Envafolimab plus S-1 - Carcinoma, Non-Small-Cell Lung | Phase 2 | Unknown | Anhui Chest Hospital | 45 | 2022-09-18 | 2022-09-07 |
| A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer Gimatecan, tegafur, gimeracil and oteracil potassium, gemcitabine - Pancreatic Cancer | Phase 2 | Unknown | Lee's Pharmaceutical Limited | 60 | 2020-12-01 | 2020-10-01 |
| CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug) - Cervical Cancer, Chemotherapy | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 200 | 2020-04-15 | 2020-03-19 |
| Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules - Gastric Cancer | Phase 2 | Unknown | RenJi Hospital | 20 | 2020-02-01 | 2019-12-17 |
| S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC） S-1 for 9 months, S-1 for 1 year - Gastric Cancer | Phase 3 | Recruiting | Fudan University | 1006 | 2019-01-01 | 2019-05-31 |
| A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites Oxaliplatin, Paclitaxel, S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules) - Gastric Cancer, Stomach Neoplasms | Phase 3 | Unknown | Fudan University | 215 | 2018-03-16 | 2018-03-23 |
| Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer S1,, Paclitaxel-albumin - Pancreatic Cancer, Neoadjuvant Chemotherapy | Phase 2 | Terminated | Zhejiang Provincial People's Hospital | 40 | 2017-11-20 | 2021-01-08 |
| Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer ApatinibMesylateTablets - Apatinib Combined, SOX | Phase 2 | Unknown | Chang-Ming Huang, Prof. | 50 | 2017-09-01 | 2020-02-05 |
| Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC HCC antigens-specific CD8+ T lymphocytes, IL-2, Tegafur - Hepatocellular Carcinoma | Phase 1 | Unknown | Beijing YouAn Hospital | 18 | 2017-05-01 | 2018-01-18 |
| Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC iNKT cells, IL-2, Tegafur - Hepatocellular Carcinoma | Phase 1 | Completed | Beijing YouAn Hospital | 10 | 2017-04-01 | 2024-09-19 |
| The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer Apatinib, S1 - Head and Neck Neoplasms | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2016-10-01 | 2016-10-24 |
Showing 20 of 31. Sign in to see all of them.
Stomach Neoplasms (11) · Pancreatic Neoplasms (3) · Carcinoma, Hepatocellular (2) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Rectal Neoplasms (1) · Uterine Cervical Neoplasms (1)
Fudan University (3) · Beijing YouAn Hospital (2) · Hallym University Medical Center (2) · Sun Yat-sen University (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Aiping Zhou (1) · Anhui Chest Hospital (1) · Beijing Biohealthcare Biotechnology Co.,Ltd (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chang-Ming Huang, Prof. (1) · Clinical Research Support Center Kyush (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · Hebei Medical University (1) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1) · LaNova Medicines Zhejiang Co., Ltd. (1)
China (23) · South Korea (3) · Japan (1)
Dae Young Zang, MD, PhD (2) · Aiping Zhou (1) · Aiping Zhou, Doctor (1) · Chunmei Bai (1) · Dazhi Xu, PHD, MD (1) · Deliang Fu (1) · Gu Yanhong, PI (1) · Haijiao Yan (1) · Haiping Jiang (1) · Hao Xu, Ph.D (1) · Jiafu Ji, MD (1) · Jieer Ying (1) · Jin Li (1) · Jing Dai (1) · Jun Lu, Director (1)
PMID 19331206, PMID 21183517, PMID 26439700, PMID 26884585, PMID 29372461, PMID 32583567, PMID 33567129, PMID 34133211, PMID 34241629, PMID 34351356, PMID 35419831, PMID 36990609, PMID 37195667, PMID 37501640, PMID 38022664, PMID 38996201, PMID 40022044, PMID 41816563